Evidence map›Paper›PMID 36976666›Full record

ReviewNeurology international2023

Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability.

Amber N Edinoff, Saveen Sall, Colby B Koontz, Ajah K Williams, DeMarcus Drumgo, Aya Mouhaffel, Elyse M Cornett, Kevin S Murnane, Alan D Kaye

Open access · goldAbstract readReview
In one paragraph

Review in Neurology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Amber N EdinoffDepartment of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-7436-6206
Saveen SallDepartment of Psychiatry and Behavioral Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Colby B KoontzSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Ajah K WilliamsSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
DeMarcus DrumgoSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Aya MouhaffelDepartment of Anesthesiology, Louisiana State Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Elyse M CornettDepartment of Anesthesiology, Louisiana State Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0001-7961-3931
Kevin S MurnaneLouisiana Addiction Research Center, Shreveport, LA 71103, USA.ORCID 0000-0002-8143-0541
Alan D KayeLouisiana Addiction Research Center, Shreveport, LA 71103, USA.
Louisiana State University Health Sciences Center Shreveport · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While driving under the influence of drugs, drivers are more likely to be involved in and cause more accidents than drivers who do not drive under the influence. Ketamine is derived from phencyclidine and acts as a noncompetitive antagonist and allosteric modulator of N-methyl-D-aspartate receptors. Ketamine has been used to treat a variety of psychiatric disorders, with the most notable being treatment-resistant depression. With the rise of at-home ketamine treatment companies, the safety of unsupervised administration remains under evaluation. A study with ketamine and a ketamine-like medication, rapasitnel, showed that those who were given ketamine experienced more sleepiness and had decreased self-reported motivation and confidence in their driving abilities. Moreover, there seem to be significant differences in the acute versus persistent effects of ketamine, as well as the anesthetic versus subanesthetic doses, both in terms of effects and outcomes. These divergent effects complicate the clinical uses of ketamine, specifically involving driving, drowsiness, and cognitive abilities. This review aims to describe not only the various clinical uses of ketamine but also the potentially detrimental effects of driving under the influence, which should be understood to help with counseling the patients who use these substances, both for their well-being and to protect public safety.

Indexed as

attentioncognitive abilitiesdrivingketamine

Identifiers

PMID36976666
PMCPMC10054038
OpenAlexW4323046764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.